Dr. Pinilla Alba on Safety Findings of the PARTNER Trial in Breast Cancer

Karen Pinilla Alba, MD, medical oncologist and clinical research fellow at University of Cambridge, discusses the safety findings stages 1 and 2 of the phase II/III PARTNER trial in triple negative and/or germline BRCA-mutated breast cancer.

The PARTNER trial examined the data collected from patients in the first 2 phases of the trial who received olaparib (Lynparza). The results showed that although adverse events were common, the majority of them were grade 1 or 2 and 5% were grade ≥3, explains Pinilla.

The safety data presented at the 2019 San Antonio Breast Cancer Symposium does not provide a comparison with a control arm, but Pinilla believes the number of grade ≥3 adverse events reported did not exceed expectations according to previous clinical trials that assess platinum-based chemotherapy in the neoadjuvant setting.

<<< View more from 2019 San Antonio Breast Cancer Symposium